Fiche centre
Novartis Investigative Site
Sheffield — United Kingdom
Essais liés7clinical trials
VilleSheffieldlocalisation
PaysUnited Kingdomlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07517263
Essais cliniques associés
7| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL | Maladie coronarienne | Phase 3 | NCT05739383 | A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. | ACTIVE_NOT_RECRUITING |
| Pelacarsen (TQJ230) | Accident vasculaire cérébral | Phase 3 | NCT07517263 | An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) | ACTIVE_NOT_RECRUITING |
| rapcabtagene autoleucel | Lupus | Phase 2 | NCT06581198 | A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) | ACTIVE_NOT_RECRUITING |
| VHB937 | Sclérose latérale amyotrophique | Phase 2 | NCT06643481 | ASTRALS — A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) | ACTIVE_NOT_RECRUITING |
| YTB323 | Myasthénie | Phase 1/2 | NCT06704269 | Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Remibrutinib oral treatment | SEP | Phase 3 | NCT06846281 | Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | RECRUITING |
| RAD001 | Épilepsie | Phase 3 | NCT01713946 | A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures | COMPLETED |